OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
- Conditions
- Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT03386994
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valladolid, Valladolid, Spain
🇪🇸H. de Manacor, Mallorca, Spain
🇪🇸Hospital Costa del Sol, Marbella (Málaga), Spain
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 69
- Registration Number
- NCT03385564
- Locations
- 🇬🇷
University General Hospital Attikon, Athens, Greece
🇯🇵Okayama University Hospital, Okayama, Okayama, Japan
🇲🇽Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03382509
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
Comparative Effectiveness of COPD Treatments
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: LABA and an ICS (LABA-ICS)
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3954
- Registration Number
- NCT03376295
- Locations
- 🇨🇦
Centre for Clinical Epidemiology, McGill University, Montreal, Canada
Afatinib Osimertinib Sequencing NIS
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT03370770
- Locations
- 🇦🇹
Otto-Wagner Hospital, Vienna, Austria
Comparative Effectiveness of Empagliflozin in the US
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230000
- Registration Number
- NCT03363464
- Locations
- 🇺🇸
Bringham Women Hospital, Boston, Massachusetts, United States
PraxbindTM India PMS Program
- Conditions
- Thromboembolism
- Interventions
- Drug: PraxbindTM
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5
- Registration Number
- NCT03359889
- Locations
- 🇮🇳
Mazumdar Shaw Medical centre, Bangalore, India
🇮🇳Care Hospital, Hyderabad, India
🇮🇳Columbia Asia Referral Hospital, Bengaluru, India
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 264
- Registration Number
- NCT03351244
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC (CNS), Torrance, California, United States
🇺🇸Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 57
- Registration Number
- NCT03349723
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT03343704
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Cardiovascular Institute and Fu Wai Hospital, Beijing, China
🇨🇳Beijing AnZhen Hospital, Beijing, China